Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Healthequity (HQY) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Healthequity (HQY) over the last 13 years, with Q4 2025 value amounting to $38.8 million.

  • Healthequity's Depreciation & Amortization (CF) fell 476.66% to $38.8 million in Q4 2025 from the same period last year, while for Oct 2025 it was $155.2 million, marking a year-over-year decrease of 373.68%. This contributed to the annual value of $162.5 million for FY2025, which is 612.3% up from last year.
  • According to the latest figures from Q4 2025, Healthequity's Depreciation & Amortization (CF) is $38.8 million, which was down 476.66% from $38.5 million recorded in Q3 2025.
  • Healthequity's 5-year Depreciation & Amortization (CF) high stood at $43.6 million for Q3 2024, and its period low was $30.4 million during Q1 2021.
  • Over the past 5 years, Healthequity's median Depreciation & Amortization (CF) value was $38.8 million (recorded in 2022), while the average stood at $38.0 million.
  • In the last 5 years, Healthequity's Depreciation & Amortization (CF) skyrocketed by 2763.08% in 2022 and then crashed by 1182.3% in 2025.
  • Over the past 5 years, Healthequity's Depreciation & Amortization (CF) (Quarter) stood at $33.5 million in 2021, then grew by 20.73% to $40.5 million in 2022, then dropped by 6.72% to $37.8 million in 2023, then rose by 7.78% to $40.7 million in 2024, then decreased by 4.77% to $38.8 million in 2025.
  • Its last three reported values are $38.8 million in Q4 2025, $38.5 million for Q3 2025, and $38.7 million during Q2 2025.